Shahid Randhawa, MD
Allergy · Fort Lauderdale, FLNPI 1376532580
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (36.6%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by Alk-abello, Inc at 44.0% of the total. Reporting peaked in 2019 at $3,056 and has fallen 93.8% since, to $189 in 2025.
Across 103 payments — averaging $60.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alk-abello, Inc$3K
- Genentech USA, Inc.$2K
- GSK$450
- Sanofi$298
- Novartis$244
- Regeneron Healthcare Solutions, Inc.$231
- plus $561 from 6 others
Across 12 payments — averaging $7079.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$67K
- AbbVie$9K
- Vanda Pharmaceuticals Inc.$7K
- Kowa Research Institute, Inc.$3K
What the payments were for
- Consulting fees$1,72528%
- Travel & lodging$2,20635%
- Food & beverage$2,29437%
- Education$371%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alk-abello, Inc | 22 | $2,753 |
| Genentech USA, Inc. | 1 | $1,725 |
| GSK | 23 | $450 |
| Sanofi | 10 | $298 |
| Novartis | 10 | $244 |
| Regeneron Healthcare Solutions, Inc. | 10 | $231 |
| AstraZeneca | 11 | $224 |
| Optinose US, Inc. | 7 | $148 |
| Pfizer | 4 | $77 |
| Kaleo, Inc. | 3 | $63 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $28 |
| Boehringer Ingelheim | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Dust mite (D. farinae)$2,206
- XOLAIR$1,725
How this compares
$6,261 in reported general payments places this provider in the 65th percentile of 56 allergy providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 11 | $47,185 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 36 | $25,353 |
| Spiriva RespimatTiotropium Bromide | 24 | $14,669 |
| Arnuity ElliptaFluticasone Furoate | 40 | $8,475 |
| SymbicortBudesonide/Formoterol Fumarate | 28 | $7,347 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 36 | $6,370 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $6,048 |
| Azelastine Hcl | 125 | $4,712 |
| BreynaBudesonide/Formoterol Fumarate | 25 | $3,767 |
| Ipratropium Bromide | 96 | $2,250 |
| Wixela InhubFluticasone Propion/Salmeterol | 23 | $1,869 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 65 | $1,561 |
| Montelukast Sodium | 73 | $723 |
| Prednisone | 38 | $42 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Arnuity Ellipta, Breo Ellipta | $450 | $39,87688 claims |
| Boehringer IngelheimSpiriva Respimat | $21 | $14,66924 claims |
| AstraZenecaSymbicort | $224 | $7,34728 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 56 allergy providers in Florida.
Other allergy in Fort Lauderdale
- Miguel LanzCoral Gables$778K
- Brett StanalandNaples$575K
- David RoseEglin Afb$253K
- Pavana BeerelliRockledge$61K
- Hugh WindomSarasota$37K
- Patrick de MarcoOrange Park$23K
- Mark MinorMelbourne$21K
- Alan KoterbaNorth Palm Beach$16K
- Brian WilsonTallahassee$11K
- Sanjay SwamiJacksonville$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.